论文部分内容阅读
目的:研究并分析复方a-酮酸片联合卡托普利治疗糖尿病肾病临床蛋白尿的临床疗效。方法:将2016年5月-2017年4月在我院接受治疗的40例糖尿病肾病患者作为研究主体,按照入院顺序分为A、B两组,每组各20例。A组患者仅使用卡托普利进行治疗,在A组的基础上给予B组复方α-酮酸片联合治疗。结果:给予复方α-酮酸片联合卡托普利治疗的B组治疗总有效率(95%)明显高于A组(70%),对比有差异,具有统计学意义(P<0.05)。结论:给予糖尿病肾病患者使用复方α-酮酸片联合卡托普利进行治疗,可有效降低患者尿蛋白排泄量,缓解患者病情,临床效果显著,值得广泛推广。
Objective: To study and analyze the clinical efficacy of compound a-ketoacid tablets combined with captopril in the treatment of clinical proteinuria of diabetic nephropathy. Methods: Forty diabetic patients with diabetic nephropathy who were treated in our hospital from May 2016 to April 2017 were selected as study subjects and divided into groups A and B according to admission order, with 20 cases in each group. Patients in group A were treated with captopril only, and group B was given combination a-ketoacid tablets on the basis of group A. Results: The total effective rate (95%) in group B treated with compound α-ketoacid tablets combined with captopril was significantly higher than that in group A (70%). The difference was statistically significant (P <0.05). Conclusion: The treatment of patients with diabetic nephropathy with compound α-ketoacid tablets combined with captopril can effectively reduce urinary protein excretion and alleviate the patient’s condition, and the clinical effect is significant and worthy of widespread promotion.